Item 8.01 Other Events.

On March 22, 2023, Tenax Therapeutics, Inc. (the "Company") issued a press release announcing that the Company has been issued a patent by the United States Patent and Trademark Office (USPTO) with claims covering the use of IV levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF). A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



Exhibit No.    Description
  99.1           Press Release, dated as of March 22, 2023.
104            Cover Page Interactive Data File (embedded within the Inline XBRL
               document).





2

© Edgar Online, source Glimpses